...
首页> 外文期刊>Journal of Clinical Microbiology >Antibody response of patients with malignancies to bacteremia with gram-negative bacteria.
【24h】

Antibody response of patients with malignancies to bacteremia with gram-negative bacteria.

机译:革兰氏阴性菌对菌血症的恶性肿瘤患者的抗体反应。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Antibody response, determined by means of the indirect bacterial hemagglutination tests, was studied in 58 consecutive patients with various malignancies whose blood culture yielded growth of Enterobacteriaceae or Pseudomonas and from whom serum specimens were obtained. Of these patients 59% had a significant antibody response. The invading microorganisms were Escherichia coli in 33 and Klebsiella in 19 subjects, an antibody response being documented with essentially equal frequency (60 and 57% of the subjects, respectively). Two patients had positive blood cultures for both E. coli and Klebsiella, one of whom had a significant response to one isolate only. A specific antibody resonse was documented in 67% of the subjects from whom blood for antibody titration was obtained at least 5 days after the blood culture, but from only 21% of patients whose serum was procured during the first 5 days after the blood culture. Similarly, such an antibody response was identified in 73% of subjects with two consecutive serum specimens, but in only 28% of the patients with a single serum specimen for antibody titration. Documentation of the immune response may be of diagnostic aid in differentiating between infection and contamination even in patients with underlying malignancy and under potentially immunosuppressive therapy.
机译:通过间接细菌血凝试验确定的抗体反应,已在58例患有各种恶性肿瘤的连续患者中进行了研究,这些患者的血液培养产生了肠杆菌科或假单胞菌生长,并从中获得了血清标本。在这些患者中,有59%具有明显的抗体反应。入侵的微生物是33名大肠埃希氏菌和19名受试者中的克雷伯菌,据报道,抗体应答的发生频率基本相等(分别为受试者的60%和57%)。两名患者的大肠杆菌和克雷伯菌均有阳性血培养,其中一名仅对一种分离株有显着反应。至少有67%的受试者在血液培养后至少5天获得了用于抗体滴定的血液,但是只有21%的患者在血液培养后的前5天获得了血清,从而产生了特异性抗体共振。同样,这种抗体反应在73%的受试者中有两个连续的血清标本,但只有28%的患者中只有一个血清标本用于抗体滴定。免疫应答的记录可能有助于区分感染和污染,即使在潜在的恶性肿瘤患者和可能接受免疫抑制治疗的患者中也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号